AGN Argenica Therapeutics Limited
Healthcare · Biotechnology
· website
$0.13
52wk 0.09 – 0.34
Overall
54.3
Value
73.8
Growth
100.0
Health
50.0
Quality
24.2
Momentum
3.5
Dividend
—
Price
About Argenica Therapeutics Limited
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.
Price analytics
Returns
| 1 day | -7.1% |
| 1 week | -13.3% |
| 1 month | -27.8% |
| 3 months | 23.8% |
| 6 months | -10.3% |
| 1 year | -48.0% |
| 3 years | -64.4% |
Risk
| Volatility (1y ann.) | 98.5% |
| Beta vs ASX 200 | -0.00 |
| Sharpe (1y) | -0.23 |
| VaR 95% (1-day) | -9.1% |
| Max drawdown (1y) | -73.1% |
| Off 1-year high | -61.2% |
Technicals
| RSI(14) | 30 OS |
| vs 50DMA | -23.0% |
| vs 200DMA | -30.1% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
73.8
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
—
Price / Book
72
Price / Sales
76
Growth
100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
50.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)
24.2
Return on equity
0
Return on assets
0
Operating margin
100
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
3.5
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
17
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$16.70M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.78
EV / EBITDA
—
Price / Book
2.83
ROE
-20.8%
Operating margin
48.0%
Net margin
-24.9%
Total cash
$6.36M
Total debt
$0
Current ratio
10.60
Debt / Equity
—
Free cash flow
$-3.81M
Avg volume
149,884
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income-$10.90M
- Net income-$7.17M
- Diluted EPS-0.06
- Free cash flow-$5.70M
- Net debt-$10.56M